{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:38:57Z","timestamp":1790433537481,"version":"4.1.0"},"reference-count":41,"publisher":"JLE","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.nephro.2020.12.006","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T18:36:51Z","timestamp":1616697411000},"page":"143-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Les inhibiteurs du SGLT2\u00a0: une nouvelle \u00e8re pour nos patients"],"prefix":"10.1684","volume":"17","author":[{"given":"Jean-Michel","family":"Halimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2020.12.006_bib0210","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0215","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMe2031382","article-title":"Finerenone\u00a0\u2013\u00a0Halting relative hyperaldosteronism in chronic kidney disease","volume":"383","author":"Ingelfinger","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0220","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.nephro.2020.12.006_bib0225","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.2337\/dc11-s202","article-title":"Impact of the US Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs","volume":"34","author":"Hirshberg","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.nephro.2020.12.006_bib0230","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0235","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0240","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0245","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0250","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0255","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000503919","article-title":"The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis","volume":"10","author":"Lo","year":"2020","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0265","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s11892-012-0275-6","article-title":"Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus","volume":"12","author":"Abdul-Ghani","year":"2012","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.nephro.2020.12.006_bib0270","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0275","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2020.12.006_bib0280","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.diabet.2012.04.001","article-title":"The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients","volume":"38","author":"Halimi","year":"2012","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.nephro.2020.12.006_bib0285","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.nephro.2020.12.006_bib0290","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0295","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0300","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0305","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0310","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s13300-020-00911-0","article-title":"Dapagliflozin for heart failure with preserved ejection fraction: will the DELIVER study deliver?","volume":"11","author":"Williams","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.nephro.2020.12.006_bib0315","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nephro.2020.12.006_bib0320","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/dom.13627","article-title":"Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: a nationwide observational study","volume":"21","author":"Norhammar","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.nephro.2020.12.006_bib0325","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","article-title":"Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (Evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world)","volume":"137","author":"Udell","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.nephro.2020.12.006_bib0330","doi-asserted-by":"crossref","first-page":"k119","DOI":"10.1136\/bmj.k119","article-title":"Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study","volume":"360","author":"Patorno","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.nephro.2020.12.006_bib0335","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","article-title":"SGLT2 inhibitors and amputations in the US FDA adverse event reporting system","volume":"5","author":"Fadini","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.nephro.2020.12.006_bib0340","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0345","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41574-019-0275-6","article-title":"SGLT2 inhibitors and urinary tract infections","volume":"15","author":"Wilding","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.nephro.2020.12.006_bib0350","doi-asserted-by":"crossref","first-page":"e2886","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives","volume":"33","author":"Qiu","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.nephro.2020.12.006_bib0355","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/jdi.12912","article-title":"Incidence and risk of vaginal candidiasis associated with sodium-glucose cotransporter 2 inhibitors in real-world practice for women with type 2 diabetes","volume":"10","author":"Yokoyama","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.nephro.2020.12.006_bib0360","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.dsx.2019.03.031","article-title":"Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes","volume":"13","author":"Yaribeygi","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.nephro.2020.12.006_bib0365","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0370","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2020.12.006_bib0375","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.nephro.2020.12.006_bib0380","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2020.12.006_bib0385","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 Trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.nephro.2020.12.006_bib0390","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2337\/dc15-1222","article-title":"Acute kidney injury predicts major adverse outcomes in diabetes: synergic impact with low glomerular filtration rate and albuminuria","volume":"38","author":"Monseu","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.nephro.2020.12.006_bib0395","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ckj\/sfz028","article-title":"Specific impact of past and new major cardiovascular events on acute kidney injury and end-stage renal disease risks in diabetes: a dynamic view","volume":"13","author":"Pinier","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nephro.2020.12.006_bib0400","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00424-020-02448-4","article-title":"SGLT2 and cancer","volume":"472","author":"Wright","year":"2020","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.nephro.2020.12.006_bib0405","first-page":"CD009966","article-title":"Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients","volume":"8","author":"Lo","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nephro.2020.12.006_bib0205","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725521000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725521000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2020.12.006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:14:13Z","timestamp":1741191253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725521000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1769725521000298"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2020.12.006","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les inhibiteurs du SGLT2\u00a0: une nouvelle \u00e8re pour nos patients","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2020.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}